JP2017515837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515837A5 JP2017515837A5 JP2016567370A JP2016567370A JP2017515837A5 JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5 JP 2016567370 A JP2016567370 A JP 2016567370A JP 2016567370 A JP2016567370 A JP 2016567370A JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antagonist
- taa
- agonist
- immunogenic combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992788P | 2014-05-13 | 2014-05-13 | |
| US61/992,788 | 2014-05-13 | ||
| PCT/US2015/029855 WO2015175334A2 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515837A JP2017515837A (ja) | 2017-06-15 |
| JP2017515837A5 true JP2017515837A5 (enExample) | 2018-06-14 |
| JP6747981B2 JP6747981B2 (ja) | 2020-08-26 |
Family
ID=53499070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567370A Active JP6747981B2 (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170266270A1 (enExample) |
| EP (1) | EP3142690B1 (enExample) |
| JP (1) | JP6747981B2 (enExample) |
| KR (1) | KR102499737B1 (enExample) |
| CN (1) | CN106456747A (enExample) |
| AU (1) | AU2015259510B2 (enExample) |
| CA (1) | CA2946418C (enExample) |
| DK (1) | DK3142690T3 (enExample) |
| ES (1) | ES2913236T3 (enExample) |
| IL (1) | IL248507B (enExample) |
| NZ (1) | NZ725459A (enExample) |
| RU (1) | RU2724433C2 (enExample) |
| WO (1) | WO2015175334A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| US10765710B2 (en) | 2014-07-16 | 2020-09-08 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| ES3011733T3 (en) * | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| US10512662B2 (en) | 2016-02-25 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| US10736962B2 (en) | 2016-02-25 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors |
| SG11201808058PA (en) * | 2016-03-18 | 2018-10-30 | Nantcell Inc | Multimodal vector for dendritic cell infection |
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| RS62589B1 (sr) * | 2016-11-02 | 2021-12-31 | Jounce Therapeutics Inc | Antitela na pd-1 i njihova upotreba |
| KR200486872Y1 (ko) | 2016-11-16 | 2018-07-10 | 김영선 | 가변형 조립식 책상 |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| JP7202362B2 (ja) * | 2017-08-24 | 2023-01-11 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
| US20210177964A1 (en) * | 2017-11-06 | 2021-06-17 | Memorial Sloan Kettering Cancer Center | Heat-inactivated vaccinia virus as a vaccine immune adjuvant |
| WO2019152922A1 (en) * | 2018-02-05 | 2019-08-08 | Nant Holdings Ip, Llc | Calreticulin and fusion proteins |
| TWI816603B (zh) * | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CN113056284A (zh) * | 2018-11-20 | 2021-06-29 | 巴法里安诺迪克有限公司 | 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3941514A4 (en) * | 2019-03-20 | 2023-08-30 | Turnstone Biologics Inc. | ONCOLYTIC VIROTHERAPY BY HETEROLOGY SEQUENTIAL BOOSTER |
| AU2020350137A1 (en) | 2019-09-20 | 2022-04-28 | Merck Patent Gmbh | Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| US20230059344A1 (en) * | 2019-11-20 | 2023-02-23 | Bavarian Nordic A/S | Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) |
| CN114867491B (zh) * | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1119354A (en) * | 1914-01-05 | 1914-12-01 | Adelbert Armstrong | Broom-holder. |
| US1391972A (en) * | 1920-08-05 | 1921-09-27 | American Cotton Oil Company | Method and apparatus for molding soap |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
-
2015
- 2015-05-08 AU AU2015259510A patent/AU2015259510B2/en active Active
- 2015-05-08 US US15/310,405 patent/US20170266270A1/en not_active Abandoned
- 2015-05-08 IL IL248507A patent/IL248507B/en unknown
- 2015-05-08 EP EP15733563.9A patent/EP3142690B1/en active Active
- 2015-05-08 CN CN201580034007.8A patent/CN106456747A/zh active Pending
- 2015-05-08 NZ NZ725459A patent/NZ725459A/en unknown
- 2015-05-08 CA CA2946418A patent/CA2946418C/en active Active
- 2015-05-08 ES ES15733563T patent/ES2913236T3/es active Active
- 2015-05-08 KR KR1020167030977A patent/KR102499737B1/ko active Active
- 2015-05-08 DK DK15733563.9T patent/DK3142690T3/da active
- 2015-05-08 WO PCT/US2015/029855 patent/WO2015175334A2/en not_active Ceased
- 2015-05-08 JP JP2016567370A patent/JP6747981B2/ja active Active
- 2015-05-08 RU RU2016148311A patent/RU2724433C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| JP2017515841A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| Lee et al. | DNA vaccines, electroporation and their applications in cancer treatment | |
| JP6535337B2 (ja) | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 | |
| Tobias et al. | Vaccination against Her-2/neu, with focus on peptide-based vaccines | |
| JP2022507744A5 (enExample) | ||
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| JP2023503857A5 (enExample) | ||
| JP2019517508A5 (enExample) | ||
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| CN108699128A (zh) | 恶性病变的组合治疗 | |
| Bhagat et al. | CEA vaccines | |
| JP2022542802A5 (enExample) | ||
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| PH12020500194A1 (en) | Malaria vaccine | |
| Kim et al. | Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC) | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Marron et al. | 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting | |
| Friedlaender et al. | A new generation of vaccines in the age of immunotherapy | |
| NZ759184B2 (en) | Methods of treating bladder cancer | |
| JP2017531699A5 (enExample) | ||
| NZ759184A (en) | Methods of treating bladder cancer |